Gilead Sciences (GILD - Free Report) closed at $65.75 in the latest trading session, marking a +1.42% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.7%. Meanwhile, the Dow gained 0.58%, and the Nasdaq, a tech-heavy index, added 0.69%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 0.87% in the past month. In that same time, the Medical sector gained 1.59%, while the S&P 500 gained 1.95%.
Investors will be hoping for strength from GILD as it approaches its next earnings release. In that report, analysts expect GILD to post earnings of $1.62 per share. This would mark year-over-year growth of 9.46%. Meanwhile, our latest consensus estimate is calling for revenue of $5.33 billion, up 4.8% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.65 per share and revenue of $22.03 billion, which would represent changes of -0.3% and -0.42%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GILD. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is holding a Zacks Rank of #4 (Sell) right now.
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.75. This valuation marks a discount compared to its industry's average Forward P/E of 22.5.
We can also see that GILD currently has a PEG ratio of 3.82. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. GILD's industry had an average PEG ratio of 1.65 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.